OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study - CORRIGENDUM
Can J Neurol Sci
.
2024 Jan;51(1):149.
doi: 10.1017/cjn.2023.317.
Epub 2023 Dec 18.
Authors
Guy Boudreau
1
,
Ian Finkelstein
2
,
Corrie Graboski
3
,
May Ong
4
,
Suzanne Christie
5
,
Katherine Sommer
6
,
Meetu Bhogal
7
,
Goran Davidovic
7
,
Werner J Becker
8
Affiliations
1
Centre Hospitalier Universitaire de Montréal (CHUM), Montréal, Quebec, Canada.
2
Toronto Headache & Pain Clinic, Toronto, Ontario, Canada.
3
Island Health, Brentwood Bay, British Columbia, Canada.
4
St Paul Hospital, Vancouver, British Columbia, Canada.
5
University of Ottawa (Neurology), Ottawa, Ontario, Canada.
6
AbbVie Inc., Marlow, Buckinghamshire, UK.
7
AbbVie Inc., Markham, Ontario, Canada.
8
Department of Clinical Sciences, University of Calgary, Calgary, Alberta, Canada.
PMID:
38105013
DOI:
10.1017/cjn.2023.317
No abstract available
MeSH terms
Botulinum Toxins, Type A* / therapeutic use
Chronic Disease
Humans
Migraine Disorders* / drug therapy
Quality of Life
Treatment Outcome
Substances
Botulinum Toxins, Type A